Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration

Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar Karuppagounder, Manoj Kumar, Xiaobo Mao, Joo Ho Shin, Yunjong Lee, Olga Pletnikova, Juan C Troncoso, Valina Dawson, Ted M Dawson, Hanseok Seok Ko

Research output: Contribution to journalArticle

Abstract

Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein-induced neuropathology. In mice expressing a human α-synucleinopathy-associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein-induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.

Original languageEnglish (US)
Pages (from-to)2970-2988
Number of pages19
JournalJournal of Clinical Investigation
Volume126
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Synucleins
Protein-Tyrosine Kinases
Phosphotyrosine
Parkinson Disease
abl Genes
Lewy Bodies
Mutation
Neurites
Tyrosine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. / Brahmachari, Saurav; Ge, Preston; Lee, Su Hyun; Kim, Donghoon; Karuppagounder, Senthilkumar; Kumar, Manoj; Mao, Xiaobo; Shin, Joo Ho; Lee, Yunjong; Pletnikova, Olga; Troncoso, Juan C; Dawson, Valina; Dawson, Ted M; Ko, Hanseok Seok.

In: Journal of Clinical Investigation, Vol. 126, No. 8, 01.08.2016, p. 2970-2988.

Research output: Contribution to journalArticle

@article{61446ea27e2d4380a5c2f4ba872996e7,
title = "Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration",
abstract = "Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein-induced neuropathology. In mice expressing a human α-synucleinopathy-associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein-induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.",
author = "Saurav Brahmachari and Preston Ge and Lee, {Su Hyun} and Donghoon Kim and Senthilkumar Karuppagounder and Manoj Kumar and Xiaobo Mao and Shin, {Joo Ho} and Yunjong Lee and Olga Pletnikova and Troncoso, {Juan C} and Valina Dawson and Dawson, {Ted M} and Ko, {Hanseok Seok}",
year = "2016",
month = "8",
day = "1",
doi = "10.1172/JCI85456",
language = "English (US)",
volume = "126",
pages = "2970--2988",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration

AU - Brahmachari, Saurav

AU - Ge, Preston

AU - Lee, Su Hyun

AU - Kim, Donghoon

AU - Karuppagounder, Senthilkumar

AU - Kumar, Manoj

AU - Mao, Xiaobo

AU - Shin, Joo Ho

AU - Lee, Yunjong

AU - Pletnikova, Olga

AU - Troncoso, Juan C

AU - Dawson, Valina

AU - Dawson, Ted M

AU - Ko, Hanseok Seok

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein-induced neuropathology. In mice expressing a human α-synucleinopathy-associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein-induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.

AB - Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein-induced neuropathology. In mice expressing a human α-synucleinopathy-associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein-induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.

UR - http://www.scopus.com/inward/record.url?scp=84983745648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983745648&partnerID=8YFLogxK

U2 - 10.1172/JCI85456

DO - 10.1172/JCI85456

M3 - Article

C2 - 27348587

AN - SCOPUS:84983745648

VL - 126

SP - 2970

EP - 2988

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -